Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo
about
HIV-1 induced bystander apoptosisHuman immunodeficiency virus 1 envelope glycoprotein complex-induced apoptosis involves mammalian target of rapamycin/FKBP12-rapamycin-associated protein-mediated p53 phosphorylationStructure activity relationship of dendrimer microbicides with dual action antiviral activityMutations in HIV-1 envelope that enhance entry with the macaque CD4 receptor alter antibody recognition by disrupting quaternary interactions within the trimer.Use of mutual information arrays to predict coevolving sites in the full length HIV gp120 protein for subtypes B and C.Critical involvement of the ATM-dependent DNA damage response in the apoptotic demise of HIV-1-elicited syncytia.Importance of membrane fusion mediated by human immunodeficiency virus envelope glycoproteins for lysis of primary CD4-positive T cells.Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys.Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virusMacrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity.Separation of human immunodeficiency virus type 1 replication from nef-mediated pathogenesis in the human thymusHuman immunodeficiency virus type 1 IIIB selected for replication in vivo exhibits increased envelope glycoproteins in virions without alteration in coreceptor usage: separation of in vivo replication from macrophage tropism.Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated regionPathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo.Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS.Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120.Genetic Dissection of the Host Tropism of Human-Tropic Pathogens.Longitudinal Analysis of CCR5 and CXCR4 Usage in a Cohort of Antiretroviral Therapy-Naïve Subjects with Progressive HIV-1 Subtype C Infection.An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes.Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response.Cytolysis by CCR5-using human immunodeficiency virus type 1 envelope glycoproteins is dependent on membrane fusion and can be inhibited by high levels of CD4 expression.Conformational alterations in the CD4 binding cavity of HIV-1 gp120 influencing gp120-CD4 interactions and fusogenicity of HIV-1 envelopes derived from brain and other tissuesHIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropismGeneration and evaluation of clade C simian-human immunodeficiency virus challenge stocksA biosensor assay for studying ligand-membrane receptor interactions: binding of antibodies and HIV-1 Env to chemokine receptorsAlternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages.Targeting HIV-1 gp41-induced fusion and pathogenesis for anti-viral therapyNeutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas.HIV-1 replication and pathogenesis in the human thymus.Production of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env SequencesChanges in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote.Syncytial apoptosis signaling network induced by the HIV-1 envelope glycoprotein complex: an overview.Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5HIV-1 Env Glycoprotein Phenotype along with Immune Activation Determines CD4 T Cell Loss in HIV Patients.A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutationsRole of HIV Gp41 mediated fusion/hemifusion in bystander apoptosis.Influence of long terminal repeat and env on the virulence phenotype of equine infectious anemia virus.Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain.Linkages between HIV-1 specificity for CCR5 or CXCR4 and in vitro usage of alternative coreceptors during progressive HIV-1 subtype C infection.Infection of rhesus macaques with a pool of simian immunodeficiency virus with the envelope genes from acute HIV-1 infections.
P2860
Q22241221-0AFD4BC2-2C42-4E56-A67C-5E44DF41F53AQ28361869-53CEECF6-C1F2-4AAD-B179-A8A05CFEDCD9Q28749596-531B23A2-6F06-420E-BC6F-AE44DD39606EQ30368471-FD75333D-7BD0-4531-81E0-BC1DF10EFF5BQ30401569-7DAD1436-1F58-4751-A755-537BDD2B56F8Q33344436-F29EE5F1-38BF-41C1-8B4A-019B1EE9D49AQ33787335-3D7893F7-F398-47EA-8F0A-0FA9099CCD21Q33839485-F14F238F-F512-4EAC-9B11-96E0438E6301Q33842020-A9834400-A766-4B28-82B2-CB79D587FF1BQ33847458-12274EA6-6DD6-4DE0-9D8C-6DEB29B30ACAQ33851415-7F008325-B1EB-4298-8338-FAB0EA542F61Q33854319-116434B9-D4CC-4C5C-BBDB-E1E2C54DD6F4Q33870292-E4EED76F-E3A0-40BE-9B0A-238F645AFC6FQ34007084-67C40B44-BB36-42EA-9E62-08C463042B2BQ34008699-7E48A967-86E3-4C9E-A4B3-D9D936BB8AC7Q34464860-CA3DDC1D-FA4A-4B4C-8307-058250DD2675Q34495762-69829475-C6FE-4D8A-8876-C4A93EA9A664Q34792976-9A3FF5EB-6BD6-48B1-AD98-576BAD6754CAQ34987062-3BA7E165-EC49-40C9-A09D-E70358C379D9Q34998032-D48ABA9A-D115-40AF-AA72-C27B8B967809Q35020604-083CA916-DC9F-4998-A1B2-BC3602946217Q35069459-B9FB87B8-EE08-401C-8801-1B2D7665FC56Q35076868-ED829D62-794B-4B3C-9349-111BC45120A8Q35115599-1851B3B6-9EF2-4C62-8D0C-B4B5B9A6F5C3Q35263959-686D741E-B02E-4C93-8BB8-668A29B233E0Q35274763-2C225879-0307-4400-94F7-A4CF173B5DBAQ35615810-F73D2495-C878-468B-98D2-05F50F90937AQ35677620-7CA1C183-4FB7-4351-8DF3-1023D5D6ADE4Q35716711-6F9D450D-5D41-46CA-8C40-7B2873B286B8Q35915764-028FC0A9-A497-4862-8AE5-279CC19CA3F5Q35985849-2EE6055E-A8E5-4FE8-BE09-AC760FE8B338Q36022247-42FF1DAD-52B8-4DA4-A7E8-FB1D46D2CAE2Q36476641-1E952577-DAB0-4AD3-913D-7909FB621A95Q36553805-5608260F-AA9F-408F-93AB-4053EB216CE2Q36827946-4CCC66F4-9133-41C2-9FBF-94FAF16E12C4Q36953103-40A9960C-C27D-42F8-B551-C590F32974E3Q36953913-367967A9-CD48-4479-9752-AEB542922BFFQ37191794-F1C69B16-B2C6-4717-B73E-FFBA9FC8C1BBQ37362368-7E052710-9373-44E4-A378-CB6CC5638A2EQ37442592-DC80AE83-4D84-4EE0-A4ED-1130257A7A52
P2860
Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Envelope glycoprotein determin ...... us (SHIV-KB9) passaged in vivo
@en
Envelope glycoprotein determin ...... n-human immunodeficiency virus
@nl
type
label
Envelope glycoprotein determin ...... us (SHIV-KB9) passaged in vivo
@en
Envelope glycoprotein determin ...... n-human immunodeficiency virus
@nl
prefLabel
Envelope glycoprotein determin ...... us (SHIV-KB9) passaged in vivo
@en
Envelope glycoprotein determin ...... n-human immunodeficiency virus
@nl
P2093
P2860
P1433
P1476
Envelope glycoprotein determin ...... us (SHIV-KB9) passaged in vivo
@en
P2093
B Etemad-Moghadam
E K Nicholson
J Sodroski
M Fernandes
P2860
P304
P356
10.1128/JVI.74.9.4433-4440.2000
P407
P577
2000-05-01T00:00:00Z